Clinical Trial: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Pancreatic Cancer
Study Type: INTERVENTIONAL
Official Title: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Brief Summary:
To learn if the investigational study drug, adagrasib (also called MRTX849), can help to control pancreatic cancer that has a KRAS G12 mutation.The safety and possible effects of adagrasib will also be studied.
Read more